Dr. Reddys Laboratories (RDY)
(Delayed Data from NYSE)
$78.47 USD
-1.97 (-2.45%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $78.47 0.00 (0.00%) 5:48 PM ET
4-Sell of 5 4
C Value C Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$78.47 USD
-1.97 (-2.45%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $78.47 0.00 (0.00%) 5:48 PM ET
4-Sell of 5 4
C Value C Growth B Momentum C VGM
Zacks News
Dr. Reddy's (RDY) Q2 Earnings and Revenues Increase Y/Y
by Zacks Equity Research
Dr. Reddy's (RDY) earnings and revenues increase year over year in second-quarter fiscal 2020.
Mylan (MYL) to Pay $30M to Settle SEC Charges for EpiPen
by Zacks Equity Research
Mylan (MYL) sinks after the SEC charges it for misclassification of EpiPen.
The Zacks Analyst Blog Highlights: Dr. Reddy's, WNS and Azure Power
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Dr. Reddy's, WNS and Azure Power
BridgeBio Pharma (BBIO) Jumps: Stock Rises 7.1%
by Zacks Equity Research
BridgeBio Pharma (BBIO) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Foamix Initiates Phase II Study on Acne Combination Foam
by Zacks Equity Research
Foamix (FOMX) enrolls first patient in phase II study on its topical combination foam, FCD105, for the treatment of moderate-to-severe acne vulgaris.
Is it Apt to Foray Into the Indian Stock Market?: An Analysis
by Tirthankar Chakraborty
The government of India unveils an array of concessions to spur the economy. This in turn will slash most corporate taxes to 22% while new manufacturers will pay even a lower corporate tax rate of 15%.
J&J's Prostate Cancer Drug Gets FDA Nod for Expanded Use
by Zacks Equity Research
J&J's (JNJ) sNDA seeking approval of Erleada for metastatic castration-sensitive prostate cancer is based on data from TITAN study.
Zynerba Releases Data on Epilepsy Candidate, Stock Down
by Zacks Equity Research
Zynerba (ZYNE) announces positive top-line results from the BELIEVE 1 study evaluating the efficacy and safety of Zygel in a heterogeneous group of rare and ultra-rare epilepsies.
Top Ranked Momentum Stocks to Buy for September 17th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, September 17th
What Makes Doctor Reddy's (RDY) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does Doctor Reddy's (RDY) have what it takes to be a top stock pick for momentum investors? Let's find out.
The Zacks Analyst Blog Highlights: Apple, Harmony Gold, NRG, Ryman Hospitality and Dr. Reddy's
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Apple, Harmony Gold, NRG, Ryman Hospitality and Dr. Reddy's
Top Stories of August Worth Watching in September
by Sweta Killa
We discuss some of the events that dominated the headlines in August and will be worth watching this month.
5 Stocks From the Best Performing Sectors in Q2
by Zacks Equity Research
We have shortlisted solid stocks from the top-performing sectors in Q2 that should make a great addition to your portfolio.
5 Stock-Picking Strategies to Counter Market Turbulence
by Sweta Killa
We have highlighted some stock-picking ideas from the top-ranked cohort that could prove extremely beneficial for investors by reducing the risk of a downside.
New Strong Buy Stocks for August 1st
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
Dr. Reddy's (RDY) Q1 Earnings and Revenues Increase Y/Y
by Zacks Equity Research
Dr. Reddy's (RDY) earnings and sales increase year over year in the first quarter of fiscal 2020.
Dr. Reddy's Inks Deal to Sell Neurology Branded Products
by Zacks Equity Research
Dr. Reddy's (RDY) announced that it has entered a definitive asset purchase agreement with Upsher-Smith Laboratories, LLC to sell its neurology branded products.
Dr. Reddy's Reports Positive Top-Line Data on Psoriasis Drug
by Zacks Equity Research
Dr. Reddy's (RDY) reports positive top-line results from the phase IIb study on PPC-06 (formerly referred to as XP23829) in patients with moderate to severe plaque psoriasis.
BioMarin's Vimizim Wins Nod in China for Rare Genetic Malady
by Zacks Equity Research
BioMarin's (BMRN) Vimizim gains an NMPA nod in China for addressing patients suffering Morquio A syndrome, an ultra-rare genetic condition.
New Strong Sell Stocks for May 22nd
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Dr. Reddy's (RDY) Q4 Earnings Up Y/Y, Revenues Top Estimates
by Zacks Equity Research
Dr. Reddy's (RDY) fourth-quarter earnings and sales increase year over year.
Dr. Reddy's (RDY) Earnings Rise in Q4, Revenues Beat
by Zacks Equity Research
Dr. Reddy's earnings and sales increase year over year in the fourth quarter of fiscal 2019.
Dr. Reddy's (RDY) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Dr. Reddy's (RDY) will provide updates on new generic filings and new drug applications, when it reports fourth-quarter fiscal 2019 results.
Dr. Reddy's (RDY) Inks Deal to Acquire Portfolio of 42 ANDAs
by Zacks Equity Research
Dr. Reddy's (RDY) inks agreement to acquire the yet-to-be-marketed portfolio of 42 non-marketed Abbreviated New Drug Applications (ANDAs) in the United States.
Supernus' ADHD Candidate Positive in 4th Phase III Study
by Zacks Equity Research
Supernus (SUPN) releases top-line results from the fourth phase III study on SPN-812 for the treatment of attention deficit hyperactivity disorder.